Singapore markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
301.02-2.76 (-0.91%)
At close: 04:00PM EST
302.45 +1.43 (+0.48%)
After hours: 06:54PM EST
Full screen
Trade prices are not sourced from all markets
Previous close303.78
Open304.56
Bid301.02 x 1000
Ask309.50 x 1400
Day's range300.75 - 306.40
52-week range225.28 - 325.19
Volume1,621,432
Avg. volume1,444,326
Market cap77.269B
Beta (5Y monthly)0.44
PE ratio (TTM)24.22
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7

    BOSTON, January 17, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2022 financial results on Tuesday, February 7, 2023 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (877) 270-2148 (U.S.) or +1(412) 902-6510 (International) and reference the "Vertex Pharmaceuticals Fourth Quarter 2022 Earnings Call".

  • Business Wire

    Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9

    BOSTON, January 04, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT.

  • Business Wire

    Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA

    BOSTON, December 12, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for VX-522, a messenger ribonucleic acid (mRNA) therapy targeted at treating the underlying cause of cystic fibrosis (CF) lung disease for the approximately 5,000 people with CF who cannot benefit from a cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Vertex plans to initiate a sin